Results 11 to 20 of about 3,061 (175)
Frontiers in Molecular Biosciences, 2023 Digitoxin is a cardiac glycoside used to treat heart failure and heart arrhythmia. However, its therapeutic concentration range is very narrow. High doses of digitoxin are associated with severe side effects; therefore, it is necessary to develop the ...
Mohd Sajid Ali +3 more
doaj +1 more source
Revisiting Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Trial: Lessons on Statistical Power [PDF]
Heart ViewsAlaa Rahhal, Ashfaq Patel
doaj +2 more sources
Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses
Molecules, 2021 Drug repositioning is a successful approach in medicinal research. It significantly simplifies the long-term process of clinical drug evaluation, since the drug being tested has already been approved for another condition.
Jan Škubník +3 more
doaj +1 more source
Quo vadis Cardiac Glycoside Research?
Toxins, 2021 Cardiac glycosides (CGs), toxins well-known for numerous human and cattle poisoning, are natural compounds, the biosynthesis of which occurs in various plants and animals as a self-protective mechanism to prevent grazing and predation.
Jiří Bejček +3 more
doaj +1 more source
INCREASING PRODUCTIVITY OF DIGOXIN CONTENT IN DIGITALIS LANATA EHRH "IN VITRO" [PDF]
Journal of Plant Production, 2009 Axillary buds Cultures of Digitalis lanata Ehrh were established from seedling, obtained under aseptic conditions. Shoot tip and single node explants were cultured on MS basal solid medium with various of BA concentrations.
M. H. Bekhit
doaj +1 more source
The in vivo effect of digitoxin on rat heart phosphatides*
Journal of Lipid Research, 1961 Digitoxin was shown to increase the specific activity of heart ventricle phosphatides in rats receiving simultaneously radioactive orthophosphate and digitoxin as compared to control rats not receiving digitoxin.
G.V. Marinetti, K. Temple, Elmer Stotz
doaj +1 more source
Digitoxin and its analogs as novel cancer therapeutics
Experimental Hematology & Oncology, 2012 A growing body of evidence indicates that digitoxin cardiac glycoside is a promising anticancer agent when used at therapeutic concentrations. Digitoxin has a prolonged half-life and a well-established clinical profile.
Elbaz Hosam A +4 more
doaj +1 more source
Digitoxin medication and cancer; case control and internal dose-response studies
BMC Cancer, 2001 Background Digitoxin induces apoptosis in different human malignant cell lines in vitro. In this paper we investigated if patients taking digitoxin for cardiac disease have a different cancer incidence compared to the general population. Methods Computer
Spigset Olav +3 more
doaj +1 more source
Na+/K+-ATPase Revisited: On Its Mechanism of Action, Role in Cancer, and Activity Modulation
Molecules, 2021 Maintenance of Na+ and K+ gradients across the cell plasma membrane is an essential process for mammalian cell survival. An enzyme responsible for this process, sodium-potassium ATPase (NKA), has been currently extensively studied as a potential ...
Jiří Bejček +3 more
doaj +1 more source
Cardenolide-Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non-small Cell Lung Cancer Cells. [PDF]
Small MethodsCardenolide‐functionalized extracellular vesicles enable targeted delivery of the chemotherapeutic doxorubicin to A549 lung cancer cells by binding Na+/K+‐ATPase, which is overexpressed in these cells. Surface‐modified, drug‐loaded EVs exhibit enhanced cytotoxicity compared to unmodified EVs and free drug, suggesting this system may lower the effective
Dorfner M +7 more
europepmc +2 more sources